Search

Search Constraints

You searched for: Author/Creator Melero, Ignacio

Search Results

1. 286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer. (9th November 2020)

2. 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody. (10th December 2020)

3. 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody. (9th November 2020)

4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

5. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

6. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

7. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

8. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

9. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

10. 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors. (10th December 2020)